Also known as: Raich v. Gonzales · Gonzales v. Raich, 545 U.S. 1 (2005)

Gonzales v. Raich (2005)

Supreme Court affirmed federal cannabis authority over state medical programs.

Automated fact-check pass
8 cited sources
Published
Last reviewed
How this page was made

This article is general information, not legal advice. Laws change; check current rules with official sources or a lawyer.

↯ The honest take

Raich settled whether Congress can regulate your homegrown cannabis plant — the answer is yes, because cumulative small grows affect the national market. The Court didn't say the feds must prosecute; it said they can. Since 2014, the Rohrabacher–Farr amendment has barred federal spending on prosecuting state-compliant medical use, but only in medical programs. This is a constitutional floor, not a ceiling — states can restrict cannabis, but can't protect growers from federal law.

Background

Angel Raich and Diane Monson were California residents using cannabis medically under the state's Compassionate Use Act of 1996 (Proposition 215). Strong evidence Raich used cannabis for a brain tumor and other conditions; Monson grew her own plants for chronic pain. Both had physician recommendations and complied with California law. Strong evidence [1][2]

In 2002, Drug Enforcement Administration agents raided Monson's home and destroyed her six cannabis plants, even though local sheriffs concluded she was within state law. Strong evidence [1][2] Raich and Monson sued Attorney General John Ashcroft (later replaced in the case caption by Alberto Gonzales) seeking an injunction against federal enforcement of the Controlled Substances Act (CSA) as applied to patients using cannabis grown intrastate, non-commercially, for personal medical use.

The 9th Circuit Court of Appeals ruled in their favor in 2003, holding the CSA likely exceeded congressional power as applied to this conduct. Strong evidence [2] The federal government appealed to the Supreme Court.

The case turned on the Commerce Clause of the U.S. Constitution, which grants Congress power to regulate interstate commerce. The precise question was whether that power extends to cannabis that is:

Raich's lawyers argued this was purely local, non-economic activity outside federal constitutional reach—relying on recent Supreme Court decisions like United States v. Lopez (1995) and United States v. Morrison (2000), which had narrowed Commerce Clause authority over non-economic activity. Strong evidence [3] The government countered that cumulative non-commercial home cultivation could affect the national illegal-cannabis market, bringing it within congressional power.

The ruling and reasoning

On June 6, 2005, the Supreme Court ruled 6–3 against Raich. Strong evidence [3] Justice John Paul Stevens, writing for the majority, held that Congress may regulate intrastate, non-commercial cannabis cultivation because, in aggregate, such activity substantially affects the interstate market for cannabis. Strong evidence [3]

The majority relied heavily on Wickard v. Filburn (1942), the landmark wheat-farming case in which the Court held that a farmer growing wheat for his own consumption could be regulated by the federal government because the cumulative effect of such activity affected interstate commerce. Strong evidence [3] Justice Antonin Scalia concurred separately, grounding his vote in the Necessary and Proper Clause. Strong evidence [3]

Justice Sandra Day O'Connor dissented, joined by Chief Justice William Rehnquist and Justice Clarence Thomas. Strong evidence [3] O'Connor, typically skeptical of drug-legalization arguments, emphasized federalism: she argued that states should be allowed to serve as "laboratories" for policy experiments like medical cannabis. Strong evidence [3] Justice Thomas wrote a separate dissent arguing the majority's reasoning gave Congress an open-ended license to regulate activity traditionally within state jurisdiction. Strong evidence [3]

The practical holding is unambiguous: the federal Controlled Substances Act applies throughout the United States regardless of state law. Strong evidence

Consequences and ongoing effects

Raich remains the constitutional foundation for the federal–state cannabis conflict that persists into 2026:

Federal illegality persists. Cannabis remains a Schedule I controlled substance under the Controlled Substances Act. Strong evidence Raich confirms federal authority to enforce that prohibition, in theory, anywhere in the United States, notwithstanding state legalization. Strong evidence

Banking restrictions. Federally regulated banks generally decline cannabis accounts because providing financial services to a federally illegal business creates money-laundering and regulatory compliance risk. Strong evidence [4] This is one reason many dispensaries operate as cash businesses. It is important to note that banking restrictions also stem from other federal statutes and regulations beyond the Raich decision, including the Bank Secrecy Act and FinCEN guidance. Strong evidence [4]

Tax code Section 280E. Cannabis businesses cannot deduct ordinary business expenses on federal income tax returns because they are engaged in trafficking in a Schedule I controlled substance. Strong evidence [4] This provision is not a direct result of Raich but reflects the same federal legal status.

No interstate commerce. States with legal cannabis markets cannot ship cannabis to each other, even when both have legalized it, because the CSA prohibits interstate transport. Strong evidence

Limited protection for medical use. The Rohrabacher–Farr amendment, first enacted in 2014 and renewed annually, prohibits the Justice Department from spending appropriated money to prosecute medical cannabis activity that complies with state law. Strong evidence [5] This does not repeal Raich; it simply defunds enforcement against medical programs that comply with state law. No comparable protection applies to adult-use (recreational) cannabis programs, which operate without explicit federal protection and rely on prosecutorial discretion and changing administration priorities. Weak / limited [6]

Rescheduling developments. In 2024, the DEA proposed moving cannabis from Schedule I to Schedule III. Strong evidence [7] Such a rescheduling would ease certain regulatory burdens—notably, it would likely allow cannabis businesses to deduct ordinary business expenses for tax purposes. Weak / limited However, the underlying constitutional holding of Raich—that Congress possesses authority to regulate even homegrown, non-commercial cannabis—would remain unchanged. Strong evidence

Dissent and federalism concerns

The O'Connor dissent remains the most quoted criticism of Raich. She argued that the majority's application of the Commerce Clause to non-economic, non-interstate activity was too expansive and threatened the constitutional boundary between federal and state power. Strong evidence [3] O'Connor noted that Raich and Monson were not selling cannabis; they grew it for personal medical use in full compliance with state law. Strong evidence [3]

Her "laboratories of democracy" framing—the idea that states should be permitted to experiment with different cannabis policies—has become central to modern federalism debates over cannabis legalization. While Raich does not prohibit states from legalizing cannabis, it establishes that state legalization does not shield growers or users from federal prosecution. Strong evidence [3] O'Connor's dissent anticipated that tension and rejected the majority's reasoning on constitutional grounds, though she was outvoted.

Raich's personal aftermath

Angel Raich was never prosecuted by federal authorities following the Supreme Court ruling, despite the Court's holding that federal authority existed. She pursued a follow-up constitutional challenge—Raich v. Gonzales—in the 9th Circuit, arguing a medical-necessity defense to CSA charges; the 9th Circuit rejected that claim in 2007. Strong evidence [8] Raich remained a public advocate for medical cannabis access and policy change for many years after the ruling.

The case illustrates an important legal principle: winning a constitutional case at the Supreme Court, even when the underlying facts are sympathetic, does not guarantee legislative or enforcement change.

This article is informational and is not legal advice. Federal cannabis law, state cannabis programs, enforcement priorities, and regulatory guidance evolve. If you face specific legal exposure—as a patient, caregiver, operator, employee, investor, or lender—consult a licensed attorney admitted to practice in your jurisdiction.

Information last verified: October 31, 2026.

Sources

How this page was made

Generation history

Oct 31, 2026
Fact-check pass — raised 5 flags
Oct 31, 2026
Revision
Jun 6, 2026
Fact-check pass — raised 2 flags
Jun 6, 2026
Initial draft

Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.